首页> The oncologist> First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

导出 OA

翻译打印收藏纠错

第一作者： Khanh T,Do

第一单位： Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

作者： Khanh T,Do ^[1] ; Laura Quan Man,Chow ^[2] ; Karen,Reckamp ^[3] ; Rachel E,Sanborn ^[4] ; Howard,Burris ^[5] ; Francisco,Robert ^[6] ; D Ross,Camidge ^[7] ; Conor E,Steuer ^[8] ; John H,Strickler ^[9] ; Amy,Weise ^[10] ; Jennifer M,Specht ^[2] ; Martin,Gutierrez ^[11] ; Peter,Haughney ^[12] ; Shawna,Hengel ^[12] ; Christina Louise,Derleth ^[12] ; Timothy A,Yap ^[13]

作者单位： Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ^[1] University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, USA. ^[2] City of Hope Comprehensive Cancer Center, Duarte, California, USA. ^[3] Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA. ^[4] Sarah Cannon Research Institute, Nashville, Tennessee, USA. ^[5] University of Alabama at Birmingham, Birmingham, Alabama, USA. ^[6] University of Colorado Cancer Center, Aurora, Colorado, USA. ^[7] Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA. ^[8] Duke University Medical Center, Durham, North Carolina, USA. ^[9] Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA. ^[10] Hackensack University Medical Center, Hackensack, New Jersey, USA. ^[11] Seagen Inc., Bothell, Washington, USA. ^[12] The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ^[13]

关键词 Clinical trials Fucosylation inhibitor Immunotherapy SGN-2FF Small molecule agents

医学主题词头颈部肿瘤(Head and Neck Neoplasms);肝素, 低分子量(Heparin, Low-Molecular-Weight);人类(Humans);淋巴瘤, 滤泡性(Lymphoma, Follicular);最大耐受剂量(Maximum Tolerated Dose)

DOI 10.1002/onco.13911

PMID 34288257

发布时间 2022-02-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交